Literature DB >> 17473502

Acquired factor V inhibitor responsive to corticosteroids in a patient with double cancers.

Hitoshi Endo1, Kiyotaka Kawauchi, Masahiko Tomimatsu, Daijiro Iga, Toshie Ogasawara, Masako Yasuyama, Toshihito Saito, Kuniaki Otsuka, Motohiko Aiba.   

Abstract

A 70-year-old woman suffering from HCV-related liver cirrhosis was admitted for abnormal bleeding. Laboratory findings included PT at 46.6 sec, APTT at >212 sec, factor V activity of <3%, and factor V inhibitor of 2 BU. Having experienced a persistent bleeding tendency for one month, the patient was started on prednisolone (0.8 mg/kg/day). Within a few days, the inhibitor became undetectable and clinical bleeding disappeared. Although clinical improvement was achieved, she died 6 months after the initial bleeding episode from the progression of a lung cancer. An autopsy revealed squamous cell carcinoma of the lung and hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17473502     DOI: 10.2169/internalmedicine.46.6390

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  2 in total

Review 1.  Acquired factor V inhibitors: a systematic review.

Authors:  Massimo Franchini; Giuseppe Lippi
Journal:  J Thromb Thrombolysis       Date:  2011-05       Impact factor: 2.300

2.  Acquired factor v inhibitor developing after treatment with dabigatran etexilate methanesulfonate: a case report and review of the literature.

Authors:  Yasunobu Sekiguchi; Hitomi Yoshikawa; Asami Shimada; Hidenori Imai; Mutsumi Wakabayashi; Keiji Sugimoto; Noriko Nakamura; Tomohiro Sawada; Tetsuo Ichinose; Dai Ozaki; Norio Komatsu; Masaaki Noguchi
Journal:  Indian J Hematol Blood Transfus       Date:  2014-03-06       Impact factor: 0.900

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.